Compare LEGH & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEGH | MLYS |
|---|---|---|
| Founded | 2005 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 523.2M | 2.4B |
| IPO Year | 2018 | 2023 |
| Metric | LEGH | MLYS |
|---|---|---|
| Price | $19.42 | $27.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $25.00 | ★ $47.33 |
| AVG Volume (30 Days) | 88.4K | ★ 1.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.29 | N/A |
| EPS | ★ 1.37 | N/A |
| Revenue | ★ $184,191,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.07 | N/A |
| P/E Ratio | $14.38 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $18.84 | $10.44 |
| 52 Week High | $29.45 | $47.65 |
| Indicator | LEGH | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 33.98 | 41.11 |
| Support Level | $18.93 | $26.85 |
| Resistance Level | $22.69 | $30.05 |
| Average True Range (ATR) | 0.69 | 1.76 |
| MACD | -0.26 | 0.08 |
| Stochastic Oscillator | 14.37 | 29.78 |
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.